Loading...
Market
Semaglutide as first-line treatment for diabetic CKD by mid-2025?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Recommendations published by a major medical association such as the American Diabetes Association
Story
FLOW Trial: Semaglutide 1.0mg Reduces Kidney, Cardiovascular Risks by 24% in Diabetic CKD Patients
May 24, 2024, 10:35 AM
The FLOW trial has shown that semaglutide, a GLP-1 receptor agonist, significantly reduces the risk of serious kidney outcomes, major cardiovascular events, and death among patients with type 2 diabetes and chronic kidney disease (CKD). The trial, which involved 3,533 participants over approximately three years, was stopped early due to its efficacy. Results indicated a 24% reduction in kidney disease progression and cardiovascular and kidney death. The study, published in NEJM, highlighted that a weekly 1.0mg dose of semaglutide was effective.
View original story
Similar markets
Positive results • 33%
Neutral results • 34%
Negative results • 33%
USA • 25%
India • 25%
Germany • 25%
Japan • 25%
Widely adopted • 25%
Moderately adopted • 25%
Rarely adopted • 25%
Not adopted • 25%
<10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
>30 countries • 25%
